< Back

PolyPid to Report Second Quarter 2022 Financial Results and Operational Highlights on August 10, 2022

Aug 10, 2022 at 8:30 AM EDT

PETACH TIKVA, Israel, July 27, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its second quarter 2022 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, August 10, 2022. The Company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the results and provide an update on business operations.

To access the live call via telephone, please register in advance using the link here. Upon registering, each participant will receive an email confirmation with dial-in numbers and a unique personal PIN that can be used to join the call. To ensure you are connected prior to the beginning of the call, the Company suggests registering a minimum of 10 minutes before the start of the call.

For those not planning to ask management a question, the Company recommends listening via the webcast using the link here.

Conference Call Dial-In & Webcast Information:

Date:  Wednesday, August 10, 2022
Time: 8:30 a.m. Eastern Time
Q&A participants: https://register.vevent.com/register/BI985b31488d2141f99e4e9db5d66810fd
Live Webcast: https://edge.media-server.com/mmc/p/itwzz9g3

Technology

PolyPid’s PLEX targeted drug delivery platform enables localized, controlled, continuous release of medication over prolonged periods of time for better patient outcomes.

Read More >
D-PLEX100

D-PLEX100

Provides safe and effective local antibiotic protection against SSI (surgical Site Infection) at the needed tissues or organs by administration during surgical procedures.

Read More >
D-PLEX1000

D-PLEX1000

Comprised of antibiotic eluting ß tri-calcium phosphate (ßTCP) granules, designed for bone related infections applications.

Read More >